叮噹健康與萬益藍開展獨家藥線合作 健康消費升級與精準渠道佈局深度協同
日前,叮噹健康旗下叮噹快藥與知名益生菌品牌萬益藍達成戰略合作,在北京、杭州、上海、深圳、天津、武漢、西安、鄭州,叮噹快藥成爲萬益藍全線產品藥品渠道獨家銷售。意味着叮噹健康升級供應鏈戰略已開啓一個嶄新的開端。

資料顯示,即時健康到家服務企業叮噹健康,線下擁有數百家叮噹智慧藥房,線上擁有全域即時零售服務能力,其‘專業送藥平臺’屬性以及7*24小時、28分鐘送達、專業醫生、藥師免費諮詢等口碑服務深入人心。
叮噹健康相關負責人表示:"保健食品、功能性食品是叮噹健康擴充供應鏈的重要方向。萬益藍作爲一家專研益生菌補充劑的生物科技公司,旗下多款產品受到中青年人羣的追捧,在業界具有廣泛影響力。引入萬益藍不僅可以爲用戶提供更加豐富、多元的專業腸道健康產品,也十分符合公司‘品牌力、產品力’的商品策略"。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.